SQI Diagnostics Inc. today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants.
| TORONTO, March 13, 2023 /PRNewswire/ -SQI Diagnostics Inc. (“SQI” or the “Company”) (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants (“Looking Glass”), pursuant to which Looking Glass will assist the Company with identifying potential new sources of up to $10 million of equity financing.
Michael Ciardi of Looking Glass, which has offices in New York and London, stated “I am very much impressed with the pipeline of products SQI has in development and is looking forward to the commercialization of these products to help save countless of lives in the respiratory health arena.” There can be no assurances as to whether Looking Glass will be successful in assisting the Company with any new financings nor can there be certainty with respect to the terms of any such new financing or financings. The Company will announce additional details relating to any new financing or financings in due course in the event that it is successful in negotiating and entering into definitive documentation relating to same. About SQI Diagnostics SQI Diagnostics is a leader in the science of lung health. The Company develops and manufactures respiratory health and precision medicine tests that run on SQI’s fully automated systems. The Company’s tests simplify and improve COVID-19 antibody monitoring, Rapid Acute Lung Injury testing, donor organ transplant informatics, and immunological protein and antibody testing. SQI Diagnostics is driven to create and market life-saving testing technologies that help more people in more places live longer, healthier lives. For more information, please visit www.sqidiagnostics.com. Contacts: Chief Financial Officer Investor Relations: FORWARD-LOOKING INFORMATION This press release contains certain words and statements, which may constitute “forward-looking statements” within the meaning of applicable securities laws relating to future events or future performance and reflect the current expectations and assumptions of the Company regarding its growth, results of operations, performance, business prospects and opportunities. These statements generally can be identified by use of forward-looking words such as “may”, “would”, “could”, “will”, “should”, “expect”, “plan”, “estimate”, “anticipate”, “intends”, “believe”, “potential”, or “continue” or the negative thereof or similar variations. The Company’s actual results and performance discussed herein could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, the effect of the global pandemic and consequent economic disruption, and the factors detailed in the Company’s ongoing filings with the securities regulatory authorities, available at www.sedar.com. Although the forward-looking statements contained herein are based on what we consider to be reasonable assumptions based on information currently available to us, there can be no assurance that actual events, performance or results will be consistent with these forward looking statements, and our assumptions may prove to be incorrect. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
SOURCE SQI Diagnostics Inc. | ||
Company Codes: OTC-QB:SQIDF, TorontoVE:SQD, OTC-BB:SQIDF, OTC-PINK:SQIDF |
View original content to download multimedia:
